Optison is used in contrast-enhanced ultrasound to enhance the image and reduce misdiagnosis and missed diagnosis. Currently, contrast agents are approved only for cardiac imaging, though new studies demonstrate the benefits of use in other applications such as detecting cancers, monitoring chronic gastrointestinal diseases, identifying vascular disease and diagnosing heart disease.
The ICUS, a medical society that represents cardiologists, radiologists and other physicians and imaging professionals, commends the label change that would remove the boxed warnings from both ultrasound contrast agents currently approved in the U.S.
Related Articles on Medical Devices:
FDA Approves Intuitive Surgical’s Single-Site Instrumentation for Gallbladder Surgery
Surgical Implant Mimics Periosteum to Heal Bone Injuries
Clemson University Bioengineering Lab to Study Surgical Implants, Joint Replacements
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
